Gleghorn E E, Merritt R J, Subramanian N, Ramos A
JPEN J Parenter Enteral Nutr. 1986 May-Jun;10(3):282-3. doi: 10.1177/0148607186010003282.
Cholestasis associated with total parenteral nutrition (TPN) is a serious complication of this therapy for which there is no known treatment other than beginning enteral feeds. Phenobarbital is commonly used in other cholestatic disease states, but its benefit in this syndrome has not been demonstrated. We conducted a retrospective review of phenobarbital use in neonates receiving concurrent TPN. Thirty-one noninfected neonates were studied. They were without evidence of intrinsic liver disease at the institution of exclusive TPN therapy. For the purposes of this study, TPN-associated cholestasis was defined as a serum bilirubin in excess of 3 mg/dl at postnatal age of 3 weeks or more. Fourteen of the study infants received phenobarbital therapy for neurologic indications. Sixty percent of the phenobarbital-treated infants developed TPN-associated cholestasis, as compared to 33% of the untreated patients. Phenobarbital therapy was not effective in preventing TPN-associated cholestasis.
与全胃肠外营养（TPN）相关的胆汁淤积是这种治疗方法的一种严重并发症，除了开始肠内喂养外，尚无已知的治疗方法。苯巴比妥常用于其他胆汁淤积性疾病状态，但它在这种综合征中的益处尚未得到证实。我们对接受同步TPN的新生儿使用苯巴比妥的情况进行了回顾性研究。研究了31例未感染的新生儿。在开始全TPN治疗时，他们没有内在肝病的证据。为了本研究的目的，TPN相关胆汁淤积定义为出生后3周或更晚时血清胆红素超过3mg/dl。14名研究婴儿因神经学指征接受了苯巴比妥治疗。接受苯巴比妥治疗的婴儿中有60%发生了TPN相关胆汁淤积，而未治疗的患者中这一比例为33%。苯巴比妥治疗对预防TPN相关胆汁淤积无效。
